NGALR is overexpressed and regulated by hypomethylation in esophageal squamous cell carcinoma

Clinical Cancer Research

Volumn 14, Issue 23, 2008, Pages 7674-7681

  Cui, Lei ^a   Xu, Li Yan ^a   Shen, Zhong Ying ^a   Tao, Qian ^b   Gao, Shu Ying ^a   Lv, Zhuo ^a   Du, Ze Peng ^a   Fang, Wang Kai ^a   Li, En Min ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; LIPOCALIN; MESSENGER RNA; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN RECEPTOR; UNCLASSIFIED DRUG; ACUTE PHASE PROTEIN; CELL SURFACE RECEPTOR; ISOPROTEIN; LCN2 PROTEIN, HUMAN; ONCOPROTEIN;

ALLELE; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CARCINOGENESIS; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DNA HYPOMETHYLATION; DNA METHYLATION; ENZYME ACTIVITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; BIOSYNTHESIS; CPG ISLAND; ESOPHAGUS TUMOR; GENE EXPRESSION; GENETIC TRANSFECTION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ACUTE-PHASE PROTEINS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOCALINS; PROMOTER REGIONS, GENETIC; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION;

EID: 59449088515     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0420     Document Type: Article

References (38)

1. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993;268:10425-32.
2. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S. Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol 2006; 26:287-92.
3. DikWA, van Kaam AH, DekkerT, et al. Early increased levels of matrix metalloproteinase-9 in neonates recovering from respiratory distress syndrome. Biol Neonate 2006;89:6-14.
4. Trachtman H, Christen E, Cnaan A, et al. Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury. Pediatr Nephrol 2006;21:989-94.
5. Nielsen BS, Borregaard N, Bundgaard JR,Timshel S, Sehested M, Kjeldsen L. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 1996;38:414-20.
6. Furutani M, Arii S, Mizumoto M, Kato M, Imamura M. Identification of a neutrophil gelatinase-associated lipocalin mRNA in human pancreatic cancers using a modified signal sequence trap method. Cancer Lett 1998;122:209-14.
7. Friedl A, Stoesz SP, Buckley P, Gould MN. Neutrophil gelatinase- associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem J 1999;31:433-41.
8. Lim R, Ahmed N, Borregaard N, et al. Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epi- thelio-mesenchymal transition. Int J Cancer 2007;120:2426-34.
9. Zhang H, Xu L, Xiao D, et al. Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: significant correlation with cell differentiation and tumour invasion. J Clin Pathol 2007;60:555-61.
10. Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, Friedl A. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat 2007;10.1007/s10549-007-9619-3.
11. Xu LY,Li EM, Xiong HQ,Cai WJ,ShenZY Study of neutrophil gelatinase-associated lipocalin (NGAL) gene overexpression in the progress of malignant transformation ofhuman immortalized esophageal epithelial cell. Progress in Biochemistry and Biophysics 2001;28:839-43.
12. Li EM, Xu LY, Cai WJ, Xiong HQ, Shen ZY, Zeng Y. Functions of neutrophil gelatinase-associated lipocalin in the esophageal carcinoma cell line SHEEC [in Chinese]. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2003;35:247-54.
13. Lin JL, Xu LY, Li EM, et al. Antisense blocking of NGAL gene expression affects the microfilament cytoskeleton in SHEEC Esophageal cancer cells. Prog Biochem Biophys 2004;31:409-15.
14. Xu LY, Li EM, Niu YD, et al. There areTPA response elements in-152 similar to-60 position of NGAL gene 5′ flanking region in the esophageal cancer cells EC109. Prog Biochem Biophys 2006;33:140-8.
15. Devireddy LR, Gazin C, Zhu X, Green MR. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 2005;123:1293-305.
16. Fang WK, Xu LY, Lu XF, et al. A novel alternative spliced variant of neutrophil gelatinase-associated lipocalin receptor in oesophageal carcinoma cells. Bio-chem J 2007;403:297-303.
17. Pan Q, Xue X. The proliferation and cell cycle of a human epithelial cell line (Eca 109) from esophageal carcinoma. J Mol Cell Biol 1980;13:19-27.
18. Mok CH, Chew EC, Riches DJ, et al. Biological characteristics of a newly established human oesophageal carcinoma cell line. Anticancer Res 1987;7:409-15.
19. Wang X, Xiao F, Wang M, Zhou C, Wu M. Establishment of two human esophageal carcinoma cell lines and their cytogenetic analysis. Zhonghua Zhong Liu Za Zhi 1998;20:3-6.
20. Shen Z, Cai W, Shen J, et al. Human papilloma virus 18E6E7 in synergy with TPA induced malignant transformation of human embryonic esophageal epithelial cells. Chin J Virol 1999;15:1-6.
21. Shen Z, Cen S, Cai W, et al. Immortalization of human fetal esophageal epithelial cells induced by E6 and E7 genes ofhuman papilloma virus18. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 1999;13: 121-4.
22. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59:198-204.
23. Milde-Langosch K, Bamberger AM, Rieck G, Kelp B, Loning T. Overexpression of the p16 cell cycleinhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer ResTreat 2001;67:61-70.
24. Tao Q, Huang H, Geiman TM, et al. Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells. Hum Mol Genet 2002;11: 2091-102.
25. Yang J, Goetz D, Li JY, et al. Anirondelivery pathway mediated by a lipocalin. Mol Cell 2002;10:1045-56.
26. Kaplan J. Mechanisms of cellular iron acquisition:another iron in the fire. Cell 2002;111:603-6.
27. Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol 2005;202:199- 211.
28. Yang B, Guo M, Herman JG, Clark DP. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 2003;163:1101-7.
29. Popiela A, Keith G, Borzecki A, Popiela G, Manowiec M, Gabrys M. The meaning of the methylation of genomic DNA in the regulation of gene expression levels. Eur J Gynaecol Oncol 2004;25:145-9.
30. Paroush Z, Keshet I,Yisraeli J, Cedar H. Dynamics of demethylation and activation of the α-actin gene in myoblasts. Cell 1990;63:1229-37.
31. Kirillov A, Kistler B, Mostoslavsky R, Cedar H,Wirth T, Bergman Y A role for nuclear NF-κB in B-cell-specific demethylation of the Igκ locus. Nat Genet 1996;13:435-41.
32. Kominsky SL, Argani P, Korz D, et al. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 2003;22:2021-33.
33. To KK, Zhan Z, Bates SE. Aberrant promoter methylation of the ABCG2 gene in renal carcinoma. Mol Cell Biol 2006;26:8572-85.
34. Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F, Schmitt FC. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res 2005;11:5869-77.
35. Sato N, Maitra A, Fukushima N, et al. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res 2003;63:4158-66.
36. Litkouhi B, Kwong J, Lo CM, et al. Claudin-4 over- expression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. Neoplasia 2007;9:304-14.
37. Kovesdi I, Reichel R, NevinsJR. Role ofan adenovirus E2 promoter binding factor in E1A-mediated coordinate gene control. Proc Natl Acad Sci U S A1987; 84:2180-4.
38. Mancini DN, Rodenhiser DI, Ainsworth PJ, et al. CpG methylation within the 5′ regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site. Oncogene1998;16:1161-9.